BR112012005044A2 - composições que compreendem tramadol e celecoxib no tratamento de dor. - Google Patents

composições que compreendem tramadol e celecoxib no tratamento de dor.

Info

Publication number
BR112012005044A2
BR112012005044A2 BR112012005044A BR112012005044A BR112012005044A2 BR 112012005044 A2 BR112012005044 A2 BR 112012005044A2 BR 112012005044 A BR112012005044 A BR 112012005044A BR 112012005044 A BR112012005044 A BR 112012005044A BR 112012005044 A2 BR112012005044 A2 BR 112012005044A2
Authority
BR
Brazil
Prior art keywords
tramadol
celecoxib
treatment
pain
compositions
Prior art date
Application number
BR112012005044A
Other languages
English (en)
Other versions
BR112012005044B1 (pt
BR112012005044B8 (pt
Inventor
Enrique Portillo Salido
Sebastià Videla Ces
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012005044(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BR112012005044A2 publication Critical patent/BR112012005044A2/pt
Publication of BR112012005044B1 publication Critical patent/BR112012005044B1/pt
Publication of BR112012005044B8 publication Critical patent/BR112012005044B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a composições farmacêuticas que compreendem tramadol e celecoxib e a seus usos como medicamentos ou analgésicos, mais particulamente para o tratamento de dor severa a moderada com um componente de inflamação.
BR112012005044A 2009-10-16 2010-10-15 composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib BR112012005044B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09384004.9 2009-10-16
EP09384004A EP2311446A1 (en) 2009-10-16 2009-10-16 Compositions comprising Tramadol and Celecoxib in the treatment of pain
PCT/EP2010/006317 WO2011045075A1 (en) 2009-10-16 2010-10-15 Compositions comprising tramadol and celecoxib in the treatment of pain

Publications (3)

Publication Number Publication Date
BR112012005044A2 true BR112012005044A2 (pt) 2016-05-03
BR112012005044B1 BR112012005044B1 (pt) 2020-12-15
BR112012005044B8 BR112012005044B8 (pt) 2021-05-25

Family

ID=41566149

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005044A BR112012005044B8 (pt) 2009-10-16 2010-10-15 composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib

Country Status (34)

Country Link
US (3) US8569271B2 (pt)
EP (3) EP2311446A1 (pt)
JP (2) JP5579858B2 (pt)
KR (1) KR101688996B1 (pt)
CN (2) CN107050006A (pt)
AR (1) AR078653A1 (pt)
AU (1) AU2010306114B2 (pt)
BR (1) BR112012005044B8 (pt)
CA (1) CA2771651C (pt)
CO (1) CO6511249A2 (pt)
CY (1) CY1114960T1 (pt)
DK (1) DK2488170T3 (pt)
EC (1) ECSP12011735A (pt)
ES (1) ES2450615T3 (pt)
HK (1) HK1173379A1 (pt)
HR (1) HRP20140157T1 (pt)
IL (1) IL218096A (pt)
IN (1) IN2012DN01434A (pt)
MA (1) MA33743B1 (pt)
MX (1) MX2012003051A (pt)
MY (1) MY156275A (pt)
NZ (1) NZ598361A (pt)
PL (1) PL2488170T3 (pt)
PT (1) PT2488170E (pt)
RS (1) RS53202B (pt)
RU (2) RU2012120087A (pt)
SG (1) SG178833A1 (pt)
SI (1) SI2488170T1 (pt)
SM (1) SMT201400035B (pt)
TN (1) TN2012000059A1 (pt)
TW (1) TWI466668B (pt)
UA (1) UA108213C2 (pt)
WO (1) WO2011045075A1 (pt)
ZA (1) ZA201202151B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
US8746719B2 (en) 2010-08-03 2014-06-10 Polaris Industries Inc. Side-by-side vehicle
KR102165246B1 (ko) * 2011-04-05 2020-10-13 옵토솔브 리서치 앤드 디벨롭먼트 리미티드 안과 치료제
US20130203783A1 (en) * 2012-02-06 2013-08-08 William L. Pridgen Valaciclovir and celecoxib combination therapy for functional somatic syndromes
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CA2987272C (en) * 2015-05-28 2019-08-20 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
KR101710792B1 (ko) * 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
RU2745196C2 (ru) * 2016-05-27 2021-03-22 Др. Редди'С Лабораторис Лтд. Пероральная композиция целекоксиба для лечения боли
WO2018186650A2 (ko) * 2017-04-03 2018-10-11 주식회사 킴스헬스케어 트라마돌과 셀레콕시브를 포함한 경구투여용 이중 복합정제
US20200323780A1 (en) 2017-04-03 2020-10-15 Kims Healthcare Co., Ltd. Bilayer combination tablet for oral administration containing tramadol and celecoxib
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
MX2021013123A (es) * 2019-05-14 2021-11-18 Esteve Pharmaceuticals Sa Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol.
CN112007024A (zh) * 2019-05-28 2020-12-01 江苏恒瑞医药股份有限公司 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
AU661723B2 (en) 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
JP2002538176A (ja) * 1999-03-01 2002-11-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トラマドール物質および選択的ｃｏｘ−２阻害薬を含んで成る組成物
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003070251A1 (en) * 2002-02-19 2003-08-28 Adcock Ingram Limited Pharmaceutical combinations of cox-2 inhibitors and opiates
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
BR112012005011B8 (pt) * 2009-10-16 2021-05-25 Esteve Pharmaceuticals Sa cocristal de tramadol e celecoxib, processo para sua produção e composição farmacêutica
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs

Also Published As

Publication number Publication date
CO6511249A2 (es) 2012-08-31
EP2488170A1 (en) 2012-08-22
PL2488170T3 (pl) 2014-05-30
ES2450615T3 (es) 2014-03-25
TW201114418A (en) 2011-05-01
BR112012005044B1 (pt) 2020-12-15
ZA201202151B (en) 2012-11-28
JP5579858B2 (ja) 2014-08-27
ECSP12011735A (es) 2012-05-30
US20120172341A1 (en) 2012-07-05
CY1114960T1 (el) 2016-12-14
RU2016125895A (ru) 2018-12-05
CN102573824A (zh) 2012-07-11
IL218096A0 (en) 2012-04-30
RS53202B (en) 2014-06-30
DK2488170T3 (en) 2014-03-03
RU2707752C2 (ru) 2019-11-29
CA2771651A1 (en) 2011-04-11
IN2012DN01434A (pt) 2015-06-05
HRP20140157T1 (hr) 2014-03-28
KR101688996B1 (ko) 2016-12-22
MX2012003051A (es) 2012-05-29
EP2737898A1 (en) 2014-06-04
UA108213C2 (uk) 2015-04-10
BR112012005044B8 (pt) 2021-05-25
US20140024622A1 (en) 2014-01-23
CA2771651C (en) 2016-08-23
AU2010306114A1 (en) 2012-03-15
WO2011045075A1 (en) 2011-04-21
AU2010306114B2 (en) 2015-07-23
AR078653A1 (es) 2011-11-23
TN2012000059A1 (en) 2013-09-19
MA33743B1 (fr) 2012-11-01
IL218096A (en) 2015-02-26
JP2014221797A (ja) 2014-11-27
TWI466668B (zh) 2015-01-01
PT2488170E (pt) 2014-03-11
US8569271B2 (en) 2013-10-29
EP2311446A1 (en) 2011-04-20
JP2013507408A (ja) 2013-03-04
HK1173379A1 (en) 2013-05-16
EP2488170B1 (en) 2014-01-22
MY156275A (en) 2016-01-29
SG178833A1 (en) 2012-05-30
RU2012120087A (ru) 2013-11-27
KR20120089287A (ko) 2012-08-09
CN107050006A (zh) 2017-08-18
SMT201400035B (it) 2014-05-07
SI2488170T1 (sl) 2014-04-30
US20150150889A1 (en) 2015-06-04
RU2016125895A3 (pt) 2018-12-05
NZ598361A (en) 2014-01-31

Similar Documents

Publication Publication Date Title
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112014005358A2 (pt) composição para alívio da dor, compreendendo um agonista seletivo de trpv1, e a sua fabricação e utilização
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
BR112012030704A2 (pt) composições farmacêuticas de cocristais de tramadol e coxibs
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
IN2012DN02471A (pt)
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
SG10201501579WA (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurennine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
BR112013004690A2 (pt) 2-oxo-e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
BR112012008649A2 (pt) Composição farmacêutica e usos da referida composição
BR112012025537A2 (pt) uso terapêutico da proteína ß2m
BR112015006755A2 (pt) métodos para alívio de sintomas de esclerose múltipla baseados em composições contendo apoaequorina
BR112013023703A2 (pt) composição tópicas que compreendem diamino oxidase para o tratamento ou prevenção de doenças associadas a altos níveis de histamina que envolvem um aumento da dor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ESTEVE PHARMACEUTICALS, S.A. (ES)

B25G Requested change of headquarter approved

Owner name: ESTEVE PHARMACEUTICALS, S.A. (ES)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF